These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8836935)

  • 21. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.
    Lindgren HS; Ohlin KE; Cenci MA
    Neuropsychopharmacology; 2009 Nov; 34(12):2477-88. PubMed ID: 19606087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat.
    Hill MP; Brotchie JM
    Br J Pharmacol; 1999 Dec; 128(7):1577-85. PubMed ID: 10602339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N-methyl-D-aspartate receptor antagonist and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
    Domino EF; Sheng J
    J Pharmacol Exp Ther; 1993 Jan; 264(1):221-5. PubMed ID: 8093726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenotypic, ethologically based resolution of spontaneous and D(2)-like vs D(1)-like agonist-induced behavioural topography in mice with congenic D(3) dopamine receptor "knockout".
    McNamara FN; Clifford JJ; Tighe O; Kinsella A; Drago J; Fuchs S; Croke DT; Waddington JL
    Synapse; 2002 Oct; 46(1):19-31. PubMed ID: 12211095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
    Alachkar A; Brotchie JM; Jones OT
    Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
    Segovia G; Mora F; Crossman AR; Brotchie JM
    Mov Disord; 2003 Feb; 18(2):138-49. PubMed ID: 12539206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Do NMDA receptor-mediated changes in motor behaviour involve nitric oxide?
    Starr MS; Starr BS
    Eur J Pharmacol; 1995 Jan; 272(2-3):211-7. PubMed ID: 7713165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715).
    Layer RT; Popik P; Olds T; Skolnick P
    Pharmacol Biochem Behav; 1995 Nov; 52(3):621-7. PubMed ID: 8545484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Place conditioning of mice with the NMDA receptor antagonists, eliprodil and dizocilpine.
    Sukhotina I; Dravolina O; Bespalov A
    Eur J Pharmacol; 1998 Dec; 362(2-3):103-10. PubMed ID: 9874159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats.
    Wirtshafter D; Osborn CV
    Eur J Pharmacol; 2005 Dec; 528(1-3):88-94. PubMed ID: 16324697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice.
    Ralph RJ; Caine SB
    J Pharmacol Exp Ther; 2005 Feb; 312(2):733-41. PubMed ID: 15494551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
    Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
    Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism.
    Ballion B; Frenois F; Zold CL; Chetrit J; Murer MG; Gonon F
    Neurobiol Dis; 2009 Sep; 35(3):376-84. PubMed ID: 19501163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Behavioral and neurochemical effects of chronic administration of reserpine and SKF-38393 in rats.
    Neisewander JL; Lucki I; McGonigle P
    J Pharmacol Exp Ther; 1991 May; 257(2):850-60. PubMed ID: 2033524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic treatment with D1 and D2 dopamine receptor agonists: combined treatments interact to differentially affect brain levels of monoamines.
    Martin-Iverson MT
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Sep; 344(3):281-5. PubMed ID: 1683687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
    Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat.
    Nash JE; Hill MP; Brotchie JM
    Exp Neurol; 1999 Jan; 155(1):42-8. PubMed ID: 9918703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
    Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
    J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Electroconvulsive treatment attenuates behavioral response to SKF 38393 in reserpine-treated mice.
    Hao XZ; Mathé AA; Mathé JM; Svensson TH
    Psychopharmacology (Berl); 1990; 100(1):135-7. PubMed ID: 2296622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glutamate-dopamine interactions in the production of pilocarpine motor seizures in the mouse.
    Starr MS; Starr BS
    J Neural Transm Park Dis Dement Sect; 1993; 6(2):109-17. PubMed ID: 7906944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.